Boston Scientific hopes the third time will be the charm. The company disclosed on Tuesday yet another obstacle in the path to approval for its novel Watchman left atrial appendage closure device for the prevention of stroke in patients with atrial fibrillation. Although it has already been before two FDA advisory panels, the company said that it had been informed by the FDA that it will need to undergo yet another advisory panel before gaining approval. The news was announced by Boston Scientific’s chief financial officer at a Wells Fargo investor’s conference.
Help employers find you! Check out all the jobs and post your resume.
